Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.When insiders sell shares, it could be a preplanned sale, or could

Benzinga51minutes ago

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $250 to $255.

BenzingaJul 12 13:16 ET

Alnylam Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 -3.25% Morgan Stanley $250 → $255 Maintains Equal-Weight 07/08/2024 35.45% Canaccord Genuity $2

BenzingaJul 12 13:15 ET

Zai Lab Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 107.2% JP Morgan $43 → $38 Maintains Overweight 07/01/2024 — Cantor Fitzgerald Reiterates →

BenzingaJul 12 11:08 ET

CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)

BenzingaJul 11 07:20 ET

Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor

Seeking AlphaJul 10 16:27 ET